CMRX Chimerix Inc
Price (delayed)
$0.87
Market cap
$77.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$63.15M
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious
Highlights
The debt has contracted by 49% YoY and by 18% from the previous quarter
The EPS has plunged by 147% YoY and by 2.1% from the previous quarter
The net income has plunged by 147% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of CMRX
Market
Valuations
Earnings
Shares outstanding
89.64M
Market cap
$77.99M
Enterprise value
$63.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
541.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
438.57
Revenue
$144,000
EBIT
-$84.7M
EBITDA
-$84.71M
Free cash flow
-$67.83M
Per share
Balance sheet
Liquidity
EPS
-$0.96
Free cash flow per share
-$0.76
Book value per share
$1.74
Revenue per share
$0
TBVPS
$1.99
Total assets
$178.51M
Total liabilities
$22.93M
Debt
$827,000
Equity
$155.58M
Working capital
$131.35M
Debt to equity
0.01
Current ratio
6.94
Quick ratio
6.71
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-58,826.4%
Gross margin
100%
Net margin
-58,820.1%
Operating margin
-65,778.5%
Return on assets
-41.8%
Return on equity
-46.3%
Return on invested capital
-51%
Return on capital employed
-54.2%
Return on sales
-58,820.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CMRX stock price
How has the Chimerix stock price performed over time
Intraday
0.66%
1 week
-1.04%
1 month
5.89%
1 year
-20.91%
YTD
-9.61%
QTD
-0.68%
Financial performance
How have Chimerix's revenue and profit performed over time
Revenue
$144,000
Gross profit
$144,000
Operating income
-$94.72M
Net income
-$84.7M
Gross margin
100%
Net margin
-58,820.1%
The net income has plunged by 147% YoY and by 2.6% from the previous quarter
Chimerix's revenue has plunged by 100% YoY
The company's gross profit has shrunk by 100% YoY
The net margin has soared by 71% from the previous quarter
Growth
What is Chimerix's growth rate over time
Valuation
What is Chimerix stock price valuation
P/E
N/A
P/B
0.5
P/S
541.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
438.57
The EPS has plunged by 147% YoY and by 2.1% from the previous quarter
The stock's price to book (P/B) is 82% less than its 5-year quarterly average of 2.8
The equity has declined by 31% year-on-year and by 11% since the previous quarter
CMRX's P/S is 112% higher than its 5-year quarterly average of 253.9 but 33% lower than its last 4 quarters average of 797.8
Chimerix's revenue has plunged by 100% YoY
Efficiency
How efficient is Chimerix business performance
Chimerix's return on equity has shrunk by 164% YoY and by 12% QoQ
CMRX's return on assets has dropped by 162% year-on-year and by 11% since the previous quarter
Chimerix's ROIC has plunged by 148% YoY and by 13% from the previous quarter
The ROS has soared by 71% from the previous quarter
Dividends
What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CMRX.
Financial health
How did Chimerix financials performed over time
The current ratio has declined by 50% year-on-year and by 19% since the previous quarter
CMRX's quick ratio is down by 50% year-on-year and by 20% since the previous quarter
The debt is 99% less than the equity
The debt has contracted by 49% YoY and by 18% from the previous quarter
The equity has declined by 31% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.